40+ results for "IoT"
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2026. “Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue,” said Chad Robins,
Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 Cash and securities of $208.6 million at quarter-end provide strong financial runway CARLSBAD, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2026 financial results and highlighted business updates and upcoming milestone
Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 ~$1.6 Billion in Cash, Cash Equivalents and Investments as of September 30, 2026 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2026. “Our third quarter results demons
Sensolus Supply Chain Velocity Index: 1 in 3 Industrial Assets Sat Still for an Entire Month
-- New Sensolus index tracks how industrial assets move between suppliers and factories, finding more movement in the U.S. and a growing share of idle assets in Europe -- A measure of how much assets travel through the supply chain, from more than 100,000 tracked assets across Europe and the U.S. ATLANTA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sensolus , a provider of industrial-grade asset-tracking solutions, found that about 1 in 3 tracked industrial assets in aerospace, automotive and equipment ma
CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing with Light
Proposed new identity reflects the Company’s strategic business expansion following its acquisition of LightSolver; change subject to shareholder approval Rehovot, Israel, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its Board of Directors has approved a proposal to change the Company’s name to OptiPhi Computing Ltd., subject to shareholders approval and completion of the applicable corporate and regulatory procedures. The proposed name ref
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
ZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen’s NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027 Announced first patient dosed in the UGN-501 Phase 1 trial Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicat
Riot Platforms Reports Third Quarter 2026 Financial Results and Strategic Highlights
Executed a 15-year, 910 critical IT MW triple-net powered land lease with a leading Frontier AI Lab at Corsicana, representing approximately $28 billion in total contract value and approximately $1.8 billion in average annual rent over the initial term Riot has now leased 1,151 MW of critical IT capacity, representing approximately $38 billion of long-term contracted revenue Sold 20,264 bitcoin year-to-date for approximately $1.5 billion primarily to fund data center development; ended the quart
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor $387 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to fund operations into the second half of 2028 BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage bioph
SIKA DRIVES GROWTH IN TUNNELING AND MINING THROUGH INDUSTRYOS PARTNERSHIP
SIKA DRIVES GROWTH IN TUNNELING AND MINING THROUGH INDUSTRYOS PARTNERSHIP Sika has signed a partnership agreement with Australian IoT developer IndustryOS to expand its digital offering for tunneling and mining customers. Under this agreement, Sika will act as the global channel partner for IndustryOS’s Safecrete and Safewall branded sensor-based technologies, which monitor the strength of sprayed concrete underground in real time and help customers improve safety, quality, and productivity. Dig
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease (CeD) Completed enrollment for Cohort 2 (mucosal healing) of Phase 1b ANB033 trial in CeD; top-line data anticipated in Q1 2027 Anticipate initiating late-stage clinical trial for ANB033 in CeD in 2027 Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis; top-l
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is enrolling ahead of schedule, enabling the Company to increase enrollment and provide topline induction results for three potential best-in-indication combinations, which are expected in Q3 2027 Reported positive topline results for SPY072 in rheumatoid arthritis (“RA”) sub-study
Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter Continued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 million AVLAYAH recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation Zafinofusp alfa advancing as Denali’s second potential product, with BLA submission on track for 2027 seeking accelerated approval for Sanfilippo syndrome type A (MPS IIIA) Five Transp
ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific
Business will operate as Biomark Scientific, a leader in accessible, scalable and automated genomic workflows powered by proprietary microfluidics technology BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Global private equity healthcare specialist ARCHIMED, and Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools”), today announced the completion of ARCHIMED’s previously announced acquisition of Standard BioTools’ Microfluidics Business. As part of ARCHIMED, the business enters its next c
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
Third-quarter 2026 Rezdiffra ® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability Rezdiffra reaches a major milestone, achieving blockbuster status with year-to-date net sales of $1.1 billion As of Sept. 30, 2026, more than 55,850 patients on Rezdiffra, nearly doubling from 3Q25, reflecting continued strong prescriber adoption and high patient demand U.S. F2-F3 MASH market is accelerating, growing to more than 530,000 addr
Evestia Clinical Acquires Emtex Life Science to Further Enhance its Global Full-Service Clinical Research Capabilities
Acquisition significantly expands the depth and scale of Evestia Clinical’s established medical writing capabilities for biotech innovators and pharmaceutical companies The deal expands Evestia Clinical’s European presence LONDON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Evestia Clinical (“the Company”), a leading independent global specialist Contract Research Organization (CRO), today announced the acquisition of Emtex Life Science (“Emtex”), a specialist regulatory medical writing company headquarte
AI Advances Gene Synthesis as CRISPR Design, Protein Prediction and Synthetic Biology Become More Precise
BCC Research finds that AI is improving target selection, sgRNA design, off-target prediction, Cas protein discovery and protein function analysis, helping make CRISPR-based engineering and synthetic biology more precise, efficient and scalable. Boston, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is fundamentally transforming gene synthesis technologies, accelerating the shift from traditional experimental workflows toward data-driven, predictive, and highly automated biological en
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechno
Acorn, Remote Monitoring Provider for Generators, Cell Towers and Critical Infrastructure, Hosts Q3 Earnings Call Thursday Nov. 5th at 11am ET
BUFORD, Ga., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for generators, gas pipelines, cell tower campuses and other critical infrastructure, will report its third quarter 2026 results premarket on Thursday, November 5th and host a conference call at 11:00 a.m. ET. Jan Loeb, President & CEO, and Tracy Clifford, CFO & COO of OmniMetrix, will answer investor questions following prepared remarks. All investors are encou
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell carcinoma lesions in patients with Gorlin syndrome Strong balance sheet, ending the quarter with $1.2 billion in cash and investments Board authorizes share repurchase program of up to $400 million PITTSBURGH, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer Promotion follows recent €120 million Series D financing as Nouscom advances NOUS-209 into registration-enabling trial in Lynch Syndrome and prepares for commercial-scale manufacturing BASEL, Switzerland – November 2, 2026 – Nouscom, a clinical-stage, cancer interception focused biotech developing next-generation immunotherapies, today announces the promotion of Loredana Sia
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary Platforms Across Therapeutic Modalities: Castle Creek’s Fibroblast-Based Cell and Gene Therapy Technology with Pelthos’ Novel Platform DURHAM, N.C. and EXTON, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos” or the “Company”), a biopharmace
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets SAN DIEGO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technology Technologies will be presented at TCT 2026 in the Canon booth TUSTIN, Calif. and ST. LOUIS, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Canon Medical Systems USA, a leader in innovative diagnostic imaging solutions, and Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced a technology compatibil
NaaS Technology Inc.'s Parent Company Enters a Strategic Partnership with Tencent Cloud to Strengthen AI-Empowered Charging Services
BEIJING, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Newlinks Technology Limited (“Newlinks”), the parent company of NaaS Technology Inc. (Nasdaq: NAAS) (“NaaS” or the “Company”), announced that it signed a strategic cooperation agreement with Tencent Cloud at the 2026 Tencent Global Digital Ecosystem Summit held in Shenzhen on October 29, 2026. Under the agreement, the two parties will collaborate in cloud services, artificial intelligence (AI) and the Energy Internet of Things (Energy IoT), jointly expl
Crestline Selected to Manage Aloft by Marriott Indianapolis Downtown
FAIRFAX, Va., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Crestline Hotels & Resorts, LLC today announced it has been selected to manage the 128-room Aloft by Marriott Indianapolis Downtown . The hotel blends contemporary style with technology-focused amenities and offers convenient access to many local attractions including Massachusetts Avenue, Gainbridge Fieldhouse and the city’s downtown dining scene. The hotel’s public spaces are designed for comfort and connection, with craft cocktails at WXYZ® Bar,
Aspen Neuroscience Announces Pricing of Initial Public Offering
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson’s disease (PD), today announced the pricing of its initial public offering of 9,375,000 shares of common stock at a price to the public of $15.00 per share. All of the shares of common stock are being offered by Aspen. The gross proceeds from the offering, before deducting underwriting discounts and c
2027 Could Finally Be the Year Cancer Is on the Ropes!
AI support for childhood cancer, treatments guided by tumor biomarkers, and discoveries in Japan and South Korea highlight progress across the global cancer-research community DENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) As 2027 approaches, developments across the United States, Europe and Asia are giving patients, researchers and healthcare markets new reasons to pay attention. Artificial intelligence is helping scientists investigate treatments and connect medical knowle
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments. NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Peptide-based medicines are becoming a bigger force in the pharmaceutical industry, and the money flowing into this field reflects that shift. Obesity and diabetes treatments have put peptides in the spotlight, but the opportunity reaches much further, including cancer
LightSolver Secures Paid Collaboration with the Israel Ministry of Defense for the Development of Photonic Computing Technology
The Israel Ministry of Defense Engagement Strengthens LightSolver’s Position in the Emerging Photonic Computing Market for Defense Applications, Estimated at Up to $5 Billion Annually Rehovot, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary LightSolver Ltd. ("LightSolver"), a pioneer of pure photonic computing and developer of the Laser Processing Unit (LPU)™, has signed an agreement with the Directorate of Defense Resea
ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline
Financing led by Asabys, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF) Proceeds will accelerate the expansion of ALLOX’s high-throughput biophysics and AI drug discovery platform and the advancement of a focused pipeline of small molecules against high-value, historically difficult-to-drug protein-protein interactions and transcription factors Seasoned biotech executive and investor Morten Graugaard, Co-founder and C B O of Orbis Medicines, appoin
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd.
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd. TME Pharma receives €150,000 for 6 months of exclusivity to negotiate a definitive agreement for worldwide rights to NOX-A12 TMS Co., Ltd., a Japanese clinical stage biotechnology company, to establish a subsidiary (“Subsidiary”) to facilitate the financing and further clinical development of NOX-A12 Non-binding terms negotiated as basis for further discussions. According to these terms, TME Pharma to receive th
Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
Dosing ongoing in fully recruited dose level 2 of MP0712 Phase 1/2a study; initial safety data to be presented at North America Conference on Lung Cancer in December 2026, efficacy data expected in 2027 Emerging clinical data from lead Radio-DARPin candidate MP0712 enables strategic focus on radiopharmaceuticals Streamlining of organization, in line with corporate focus, to advance Radio-DARPin programs Cash position of CHF 57.5 million (USD ~69 million) as of September 30, 2026, expected to fun
Avaí Bio and Austrianova Announce Publication in Frontiers in Aging Journal Highlighting Novel Cell Encapsulation-Based Approach to Sustained Klotho Delivery
LAS VEGAS, NV, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its joint venture partner Austrianova, today announced the publication of a peer-reviewed article in Frontiers in Aging , entitled, “Maintaining Klotho: Preventing the Body from Unwinding .” The article, authored by Austrianova researchers, appears in the journ
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2026 and provided a business update. In early O
NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer
Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate Strategy and Investor Relations Experience ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences, Inc. (“NovaBridge” or the “Company”) (NASDAQ: NBP) today announced the appointment of Chuck Silberstein, M.D., M.B.A. as Chief Financial Officer, effective November 2, 2026. Dr. Silberstein succeeds Kyler Lei, who is stepping down following a successful tenure with the Company. Dr. Silberstein has more
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program
EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research VANCOUVER, British Columbia, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, and Boston-based Celvion Therapeutics (“Celvion”), today announced the completion of the first analysis
Pacifica Hotels Signs Franchise Agreement with Marriott International to Open Courtyard by Marriott Hida Takayama
TOKYO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pacifica Hotels G.K. today announced the signing of a franchise agreement with Marriott International to debut Courtyard by Marriott in the historical destination of Takayama, Gifu. The new property will be located in the beautiful city of Takayama, famous for Edo period architecture and the UNESCO World Heritage Site listed destination of Shigakawa-go Village, along with numerous traditions included on the UNESCO Intangible Cultural Heritage List. “Takay
CELSET Launches SOLTOX, a Korean Botulinum Toxin Type A Brand, for International Markets
SEOUL, South Korea , Oct. 28, 2026 -- CELSET INC., a Korean biotechnology company specializing in medical aesthetics, has launched SOLTOX, its botulinum toxin type A brand, introducing a Korean botulinum toxin brand to the international medical aesthetics industry. SOLTOX is presented in 100 Unit and 200 Unit formulations with three defining technical characteristics: a 900 kDa toxin complex, a freeze dried dosage form, and an advanced purification process. Together, these attributes reflect a manufacturing approach emphasizing controlled processing, product characterization, and pharmaceutical quality.
Cavli Wireless Launches Cavli360, a Collaborative Industry Magazine Connecting the Global IoT Ecosystem
SAN JOSE, Calif. , Oct. 28, 2026 -- Cavli Wireless, a global end-to-end IoT solutions provider, has launched the inaugural edition of Cavli360 , a new industry publication featuring insights, experiences, and perspectives from across the connected technology landscape. Officially launched at electronica India 2026 in Bengaluru , Cavli360 is a collaborative platform that brings together insights and perspectives from Cavli Wireless s leadership team, customers, distributors, technology partners, industry experts, and analysts to spotlight innovations, industry developments, and emerging trends shaping the future of IoT.
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced separate underwritten public offerings of $200.0 million of shares of its common stock (the “common stock offering”) and $150.0 million aggregate principal a